Article

(2021) The efficacy and safety of Ivermectin in patients with mild and moderate COVID-19: A structured summary of a study protocol for a randomized controlled trial. Trials. p. 3.

(2019) Cell cytotoxicity, immunostimulatory and antitumor effects of lipid content of liposomal delivery platforms in cancer immunotherapies. A comprehensive in-vivo and in-vitro study. International Journal of Pharmaceutics. p. 9. ISSN 0378-5173

(2019) Cytotoxicity, stimulatory and antitumor effects of liposomal delivery vehicles in cancer immunotherapies. European Journal of Immunology. pp. 1823-1824. ISSN 0014-2980

(2016) Tat peptide and hexadecylphosphocholine introduction into pegylated liposomal doxorubicin: An in vitro and in vivo study on drug cellular delivery, release, biodistribution and antitumor activity. International Journal of Pharmaceutics. pp. 236-244. ISSN 0378-5173